Fig. 1
From: Pancreatic cancer tumor organoids exhibit subtype-specific differences in metabolic profiles
PDOs capture genomic heterogeneity of patient tumors and display subtype specific alterations in metabolism. (a) Oncoprint comparing somatic mutations (SNV/indel) and copy number variation (CNV) events in frequently mutated and metabolic genes between patient tumors (T) and matched PDOs (O). (b) Scatter plot depicting correlation in expression of glycolytic genes between patient tumors and derived PDOs with basal-like or classical subtypes (spearman correlation; Benjamini–Hochberg multiple test correction). (c) Extracellular acidification rate (ECAR) curves of PDOs after injections of glucose, oligomycin and 2-DG during a Glycolysis Stress Test. There are multiple phases recorded, baseline glycolysis refers to ECAR after glucose and before oligomycin injection; maximum glycolysis refers to ECAR after oligomycin injection and before 2-DG injection; and non-glycolytic acidification (NGA) refers to ECAR before injection of glucose or after injection of 2-DG. (d) Bar plots of grouped comparison between PDOs from basal-like and classical tumors showing differences in glycolysis measurements. (e) Oxygen consumption rate (OCR) curves of PDOs after injections of oligomycin, FCCP and Rotenone + Antimycin-A during a Mito Stress Test. Multiple assay phases were recorded, baseline respiration refers to OCR prior to oligomycin injection; maximum respiration refers to OCR after FCCP injection and before Rotenone + Antimycin-A injection; ATP-linked respiration is the difference between basal respiration and OCR after oligomycin injection and before FCCP injection; and non-mitochondrial respiration (NMR) refers to OCR after injection of Rotenone + Antimycin-A. (f) Bar plots of grouped comparison between PDOs from basal-like and classical tumors showing differences in OXPHOS measurements. *p < 0.05, **p < 0.01, ***p < 0.001 (Students t-test)